CIDO, a community-based ontology for coronavirus disease knowledge and data integration, sharing, and analysis by He, Oliver et al.
1Scientific Data |           (2020) 7:181  | https://doi.org/10.1038/s41597-020-0523-6
www.nature.com/scientificdata
CIDO, a community-based 
ontology for coronavirus disease 
knowledge and data integration, 
sharing, and analysis
Yongqun He  1 ✉, Hong Yu2,3, Edison Ong1, Yang Wang1,2,3, Yingtong Liu1, anthony Huffman1, 
Hsin-hui Huang1,4, John Beverley  5, Junguk Hur  6, Xiaolin Yang7, Luonan Chen8,9, 
Gilbert S. Omenn1, Brian athey1 & Barry Smith10
the Coronavirus Infectious Disease Ontology (CIDO) is a community-based ontology that 
supports coronavirus disease knowledge and data standardization, integration, sharing, and 
analysis.
Ontologies, as the term is used in informatics, are structured vocabularies comprised of human- and computer-interpretable terms and relations that represent entities and relationships. Within informatics fields, ontologies play an important role in knowledge and data standardization, representation, integra-
tion, sharing and analysis. They have also become a foundation of artificial intelligence (AI) research. In what 
follows, we outline the Coronavirus Infectious Disease Ontology (CIDO), which covers multiple areas in the 
domain of coronavirus diseases, including etiology, transmission, epidemiology, pathogenesis, diagnosis, preven-
tion, and treatment. We emphasize CIDO development relevant to COVID-19.
Human coronaviruses have given rise to a series of major crises in global public health. Severe acute respira-
tory syndrome (SARS) emerged in China in November 2002, lasted for eight months and resulted in 8,098 con-
firmed human cases in 29 countries with 774 deaths (case-fatality rate: 9.6%)1. Approximately ten years later in 
June 2012, the Middle East Respiratory Syndrome (MERS), another highly pathogenic coronavirus disease, was 
identified in Saudi Arabia. The MERS outbreak has caused 2,260 cases in 27 countries and 803 deaths (35.5%)2. 
More recently, the World Health Organization (WHO) declared the Coronavirus Disease 2019 (COVID-19) out-
break as a pandemic on March 11, 2020, when there were 118,326 confirmed cases and 4,292 deaths. As of May 
13, there have been over 4.4 million confirmed cases and over 295,000 deaths globally. Unfortunately, we still do 
not have available effective drugs and vaccines against these highly pathological coronaviruses.
Extensive studies have been conducted on coronaviruses, the results of many of which exist in publicly avail-
able data repositories such as GEO3. Publications concerning COVID-19 have exploded in recent months, and 
new clinical trials have been and are being conducted to develop drugs and vaccines against COVID-19, 1,430 
of which have been registered in ClinicalTrials.gov as of May 13, 2020. As of May 13, 2020, a PubMed search of 
“SARS”, “MERS”, and “SARS-CoV-2 OR COVID-19” resulted in 12,993, 4,493 and 11,813 publications, respec-
tively. A coordinated study of all such results would likely help with understanding and developing treatments 
for COVID-19. This coordinated study requires the integration of the large and exponentially growing data 
and research concerning COVID-19 to better understand its etiology, transmission, and pathogenesis mecha-
nism. Moreover, we must be able to translate that understanding into rapid development of patient stratification 
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methods leveraging precision medicine, therapeutic drugs, and preventive vaccines. However, there are two bot-
tlenecks to achieving these tasks:
First, the characteristic five V’s of our Big Data4 era lead to disintegrated and non-interoperable data and 
knowledge. The amount of data (volume), speed at which it is produced (velocity), range of its sources (variety), 
quality and accuracy (veracity), and assessment of utility (value), result in large, complex, multidimensional, and 
diverse datasets. Disintegrated and non-interoperable data cannot be interpreted by computers and this inhibits 
computer-assisted reasoning, which is the essence of artificial intelligence. Consequently, our knowledge – data 
and information that embodies awareness and understanding – of domains represented by various datasets is 
seriously hindered. This is a familiar problem for biomedical research in general, which relies heavily on data 
acquisition, and for coronavirus research in particular, given the global challenge we currently face. The second 
bottleneck is the lack of bioinformatics tools that can efficiently and robustly integrate and analyze heterogeneous 
data and knowledge. This is likely a major stumbling block that is slowing the discovery of effective measures 
against coronaviruses even despite extensive effort across the globe.
A critical key to data/information/knowledge disintegration and big data analysis is ontologies. Ontologies 
are widely used in biomedical data and metadata standardization, and robustly support data integration, sharing, 
reproducibility, and computer-assisted data analysis. Ontologies are also regarded as the foundation of knowl-
edge representation and reasoning (KR², KR&R), a major field of artificial intelligence. An important biomedical 
example is the Gene Ontology (GO)5, which was originally developed in the late 1990s by researchers studying 
the genomes of three model organisms: fruit fly, mouse, and yeast (Saccharomyces cerevisiae), but later extended 
to provide terms and relations used to annotate genes from humans, plants, animals, and microbes. GO includes 
three branches, for cellular components, molecular functions, and biological processes, forming a controlled vocab-
ulary that can be used to represent attributes of gene products in a species-neutral way. Many GO-based tools and 
algorithms have been developed6. Since publication in 2000, the original GO paper5 has been cited some 25,000 
times. GO makes possible consistent and reproducible annotations and analyses of genes and genomes from and 
across different organisms.
The success of GO inspired the development of hundreds of biomedical ontologies over the past two dec-
ades7. Included among those ontologies are many relevant to COVID-19: the Disease Ontology (DOID)8 classi-
fies 18,000 human diseases now including COVID-19; the Human Phenotype Ontology (HPO)9 defines 26,000 
human phenotypes; the Chemical Entities of Biological Interest ontology (ChEBI)10 includes 135,000 chemical 
entities; the Ontology for General Medical Sciences (OGMS) includes 200 terms for general medical classifica-
tion; and the Ontology for Biomedical Investigations (OBI)11 includes nearly 4,000 terms related to all aspects 
of biomedical investigations. All these ontologies can be applied to the study of coronavirus diseases. Of most 
relevance to us here is the Infectious Disease Ontology (IDO)12, which defines 550 terms relating to infectious 
diseases in general and provides a basis for more specific IDO ontologies, for flu, malaria, brucellosis, and other 
diseases.
Ontology openness and interoperability are critical for data sharing and integration. The FAIR Guiding 
Principles propose that all research data should be Findable, Accessible, Interoperable and Reusable (FAIR) for 
both machine and human users13. “Interoperability” is the basis of the four FAIRness principles, which see ontol-
ogy interoperability as the foundation of data/information/knowledge interoperability. With hundreds of ontol-
ogies developed, many ontologies overlap each other but, unfortunately, are not interoperable. Many ontologies, 
through lack of interoperability with other, more widely used ontologies, form silos and thereby fail to support 
integrative research. To foster interoperability, the Open Biomedical and Biological Ontologies (OBO) Foundry 
was initiated in 2007 by ontology developers who agreed to adopt a set of principles – including the commitment 
to collaboration and openness, use of definitions in both human- and computer-readable formats – specify-
ing best practices in ontology development14. The OBO ontology library includes approximately 200 ontologies 
(including GO).
To meet the challenge of COVID-19, we recently initiated the development of CIDO, a community-driven 
open-source biomedical ontology in the area of coronavirus infectious disease (https://github.com/
CIDO-ontology/cido). CIDO provides standardized human- and computer-interpretable annotation and rep-
resentation of various coronavirus infectious diseases, including their etiology, transmission, epidemiology, 
pathogenesis, host-coronavirus interactions, diagnosis, prevention, and treatment. CIDO will be used as a 
state-of-the-art knowledge base for standard and logical representation of heterogeneous coronavirus knowl-
edge. Having been accepted as an OBO library ontology, CIDO follows the OBO Foundry principles14, and uses 
an OBO-compatible extensible ontology development strategy15. To support data interoperability, CIDO reuses 
relevant coronavirus terms from existing reliable reference ontologies themselves aligning with OBO Foundry 
principles, and aligns these terms under the Basic Formal Ontology (BFO)16, an ISO/IEC standard 21838-2 
(https://www.iso.org/standard/74572.html) top-level ontology. BFO is a realism-based ontology that covers all 
domains by providing highly general ontology classes such as material entity, process, role, site, and so forth. By 
using BFO as its upper-level architecture, CIDO is automatically interoperable and integrated with >300 other 
ontologies that also align with BFO. Currently, CIDO contains over 4,000 terms, imported from some 20 further 
ontologies such as ChEBI, Human Phenotype Ontology, Disease Ontology8, and the NCBI taxonomy ontology 
(NCBITaxon). Additionally, new CIDO-specific terms have been developed to meet the special needs arising in 
the research of COVID-19 and other coronavirus diseases.
Developing robust ontologies adequate for representing complex domains requires more than the simple con-
struction of taxonomies. Taxonomies reflect important hierarchical relationships among class and subclass terms, 
represented using is_a relations. For example, instances of coronavirus are instances of viruses, which is to say 
coronavirus is_a virus. Extending beyond taxonomies, ontologies provide additional relations among entities 
within and across domains. Figure 1 illustrates a general design of how we can logically link ontology terms that 
may come from different branches of CIDO. The relations along the arrows in Fig. 1 are computer-understandable 
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links between ontology classes. For example, we can define a logical axiom using the ‘caused by’ relation to link 
the COVID-19 disease process and SARS-CoV-2 virus:
COVID-19 disease process: ‘caused by infection with’ some SARS-CoV-2
Such an axiom defines the causal relation between the COVID-19 disease process and the virus strain 
SARS-COV-2. More specifically, the development of the COVID-19 disease process (or realization of the 
COVID-19 disease disposition) in a patient is causally induced by an infection of the SARS-CoV-2 virus in the 
patient, involving viral invasion of and replication in host cells. In CIDO, diseases such as COVID-19 and path-
ogens such as SARS-CoV-2 have distinct hierarchies, with relations linking terms in these hierarchies. The inclu-
sion of the relations (e.g., ‘caused by infection with’) in addition to is_a greatly expands expressiveness, reasoning 
capabilities, and expected inferences.
Figure 1 illustrates many other key relations. Particularly, COVID-19 occurs in the lung, and some genes in the 
cells of the lung would have the disposition of being susceptibly up- or down-regulated in the cells of SARS-CoV-
2-infected lung. Such genes may function as gene markers and play important roles in pathogenesis. In addition, 
the infected patient will display different phenotypes after manifesting the disease, and such phenotypes may be 
associated with other patient attributes (e.g., biological sex, age) and the patient’s gene profile. CIDO thus pro-
vides semantically interoperable representations of host-coronavirus interaction mechanisms. Although Fig. 1 
provides only a high-level overview of some CIDO resources, more details, such as specific signature genes in 
some cells of the lung that are susceptible to be up- or down-regulated in patients with COVID-19 will be added 
to the CIDO as new knowledge is acquired. Such systematic modeling and representation of the host-coronavirus 
interaction mechanisms would facilitate rational design of anti-coronavirus drugs and vaccines17,18.
In pursuit of that aim, CIDO can logically define relations between drugs and roles or mechanisms of action 
– distinct hierarchies in CIDO – and so support advanced analysis of potential drugs used to treat COVID-19, 
as well as the quick query of drugs having specific roles or mechanisms of action potentially useful as treatments. 
Such application of CIDO for ontology-based integration and analysis of anti-coronavirus drugs is shown in our 
recent preprint paper17. Using literature mining we identified 72 chemical drugs and 27 monoclonal or polyclonal 
antibodies that have anti-coronavirus effects in experimental studies in vivo or in vitro. Many of these drugs were 
mapped to three ontologies: Chemical Entities of Biological Interest ontology (ChEBI)10, National Drug File – 
Reference Terminology (NDF-RT)19, and the Drug Ontology (DrON)20. The subbranches of these ontologies that 
contain the mapped drugs and their related characteristics were extracted using the Ontofox tool21. Key informa-
tion was identified by examining these subbranches. For example, based on their ChEBI annotations, many drug 
active ingredients are classified under the same chemical group: for example, chlorpromazine, dasatinib, tercona-
zole, and chloroquine, all organochlorine compounds. Meanwhile, ChEBI classifies many drug chemicals having 
the same roles: chloroquine, conessine, lycorine, and mefloquine, all exhibit antimalarial activity. A ChEBI-based 
semantic similarity calculation method clustered 60 drugs into five major categories. The chemical information 
in ChEBI has also been imported to DrON. Developed by the U.S. Department of Veterans Affairs, Veterans 
Health Administration (VHA), NDF-RT organizes drugs by means of a formal representation of various drug 
characteristics such as mechanism of action (MoA), physiologic effect, and related diseases19. Using NDF-RT, 
we found that, of 35 drugs that have MoA annotations, 34 have MoAs of various inhibitors and antagonists. One 
shortcoming is that none of these ontologies covers all the needed information pertaining to our identified drugs. 
To study the anti-coronavirus drugs in a thorough manner we will need to identify and ontologically represent 
missing information of the sort that falls under the domain of the CIDO ontology. Thus, we plan to build logical 
relations linking drugs, coronaviruses, and the conditions under which the drugs work against the coronaviruses.
Another example of our ongoing work is the use of CIDO for the representation of vaccines against coronavi-
ruses. We recently released another preprint paper on COVID-19 vaccine design using reverse vaccinology and 
machine learning18. Data pertaining to experimentally verified vaccine candidates in laboratory animal models 
Fig. 1 The design pattern of CIDO for logically representing and linking different components related to a 
coronavirus disease, e.g., COVID-19. The terms presented in the figure are generated in CIDO or imported by 
CIDO from other ontologies. To reduce complexity, the ontology sources of the terms are not labeled.
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have also been collected and annotated18. We will systematically annotate these vaccine candidates, including 
their formulations and host responses, and work with the Vaccine Ontology (VO) development team to model, 
represent, and analyze these vaccines (http://www.violinet.org/vaccineontology/). Moreover, CIDO can be used 
alongside VO to support literature mining of vaccine-associated gene-gene interactions22.
In future research, we will use ontology-based approaches to investigate relevant host-coronavirus interac-
tions to support the fundamental understanding of the disease and protective immune system mechanisms, pre-
cision medicine research, and rational vaccine design23,24. More broadly, CIDO will provide community-based 
metadata standardization for interoperable and reproducible clinical and experimental studies, insofar as the 
coronavirus metadata ontology will be extracted from CIDO as a lightweight and relatively independent ontol-
ogy to support data integration and knowledge discovery. We will use the standard to analyze clinical and basic 
research data and align the identified disease phenotype and transmission data with the underlying mechanisms 
introduced in other aims.
The extensive study of COVID-19 is generating new knowledge quickly. Given that our understanding of 
COVID-19 is changing rapidly, we need not only an ontology as wide in purview as CIDO, but also to be readily 
updated in a timely matter as more knowledge is generated about the disease, the virus, and the host response. 
To that end, we follow OBO Foundry guidelines for term requests and updating via issue tracking on the CIDO 
GitHub site (https://github.com/CIDO-ontology/cido). We welcome wide community participation in CIDO 
development and applications. CIDO is an open community; everyone is welcome. We are already collaborating 
with many groups and look forward to more collaborations with colleagues and people around the world. Starting 
with CIDO and its supported data integration, we expect that innovative computational and statistical algorithms 
and tools will be developed and applied to support basic studies of mechanisms, and translational applications 
such as predicting drugs and vaccines that hold promise for treating and preventing COVID-19.
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